| [1] |
Liu Y,el-Ashry D,Chen D,et al.MCF-7 breast cancer cells ove-rexpressing transfected cerbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo[J].Breast Cancer Res Treat,1995,34(2):97-117.
|
| [2] |
Tsang R,Finn R.Beyond trastuzumab:novel therapeutic strategies in HER2-positive metastatic breast cancer [J].Br J Cancer,2012,106(1):6-13.
|
| [3] |
De Santes K,Slamon D,Anderson SK,et al.Radiolabeled antibody targeting of the HER-2/neu oncoprotein [J].Cancer Res,1992,52(7):1916-1923.
|
| [4] |
Spector NL,Xia W,Burris H,et al.Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies [J].J Clin Oncol,2005,23(11):2502-2512.
|
| [5] |
Earl HM,Vallier AL,Dunn J,et al.Trastuzumab-associated cardiac events in the Persephone trial [J].Br J Cancer,2016,115(12):1462-1470.
|
| [6] |
Eryilmaz A,Demirci B,Gunel C,et al.Evaluation of lapatinib and trastuzumab for ototoxic effects [J].J Int Adv Otol,2015,11(3):207-211.
|
| [7] |
Spector NL,Xia W,Burris H,et al.Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies [J].J Clin Oncol,2005,23(11):2502-2512.
|
| [8] |
Costa RLB,Soliman H,Czerniecki BJ.The clinical development of vaccines for HER2+ breast cancer:current landscape and future perspectives [J].Cancer Treat Rev,2017,61:107-115.
|
| [9] |
Tabi Z,Man S.Challenges for cancer vaccine development [J].Adv Drug Deliv Rev,2006,58(8):902-915.
|
| [10] |
Dalgleish AG.Therapeutic cancer vaccines:why so few randomised phase III studies reflect the initial optimism of phase II studies [J].Vaccine,2011,29(47):8501-8505.
|
| [11] |
Grunewald J,Hunt GS,Dong L,et al.Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids [J].Proc Natl Acad Sci U S A,2009,106(11):4337-4342.
|
| [12] |
Dai HT,Tian H,Huang J,et al.Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice [J].J China Pharm Univ(中国药科大学学报),2017,48(4):483-489.
|
| [13] |
Kessel C,Nandakumar KS,Peters FB,et al.A single functional group substitution in C5a breaks B cell and T cell tolerance and protects against experimental arthritis [J].Arthritis Rheumatol,2014,66(3):610-621.
|
| [14] |
Cai D,Tian H,Yao WB.Molecular dynamics simulation and analysis of BAFF which is incorporated with p-nitro-L-phenylalanine[J].J China Pharm Univ(中国药科大学学报),2017,48(2):227-232.
|
| [15] |
Gauba V, Grunewald J, Gorney V, et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids [J].Proc Natl Acad Sci U S A,2011,108(31):12821-12826.
|
| [16] |
Kageyama S, Kitano S, Hirayama M, et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel [J].Cancer Sci,2008,99(3):601-607.
|
| [17] |
Hardy LL, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated analog 3′-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells [J].J Immunol,2008,180(9):5956-5962.
|
下载:
